Navigation Links
Clinical Update - Debio 9902 (ZT-1) for Alzheimer's Disease

Presentation of Final Phase I Monthly Implant and Phase IIa Daily Oral Results

LAUSANNE, Switzerland, June 11, 2007 /PRNewswire/ -- Debiopharm Group (Debiopharm), a global independent biopharmaceutical development specialist in oncology and serious medical conditions, presented final results of two Debio 9902 (formerly ZT-1) studies for the treatment of Alzheimer's disease (AD) at the Alzheimer's Association International Conference on the Prevention of Dementia, in Washington, DC:

- The phase I monthly sustained release implant study showed that Debio 9902 was well tolerated after repeated doses up to 15mg/per month and there were no safety concerns.

- The phase IIa once-daily oral study for a treatment period of 9 months showed that Debio 9902 was safe and effective in the treatment of moderate AD.

In a phase I study, healthy volunteers were administered once monthly subcutaneous injections of Debio 9902 SR implants up to 15mg. Sustained levels of Huperzine A (Hup A), the active metabolite of Debio 9902, were observed up to four weeks and Debio 9902 was well tolerated.

In a phase IIa study with the oral formulation of Debio 9902 in mild to moderate AD patients, improvements were observed on 3 efficacy scales, the assessment cognitive sub-scale (ADAS-cog), the Mini mental state examination (MMSE) and the Neuropsychiatric inventory questionnaire (NPI-Q). The study included a randomized part which lasted 3 months and which was followed by an additional 6 month open label part. The efficacy shown with the oral formulation, the good safety profile and the sustained release of Debio 9902 implants over one month have led to an ongoing phase II 'BRAINz' study in AD patients.

"The continuous release of Debio 9902 SR implants provides a new treatment alternative with the potential for better tolerance through a progressive, steady release of the active compound, therefore increasing p
'"/>




Page: 1 2 3

Related medicine technology :

1. Genetic Analysis Systems Enter the Clinical Mainstream
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
4. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
7. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Clinical Update Debio for Alzheimer Disease
(Date:8/20/2014)... YORK , Aug. 20, 2014 ... new market research report is available ... Market for Hospital-Acquired Infection Control (Sterilization, ... http://www.reportlinker.com/p01618925/The-Market-for-Hospital-Acquired-Infection-Control-Sterilization-Disinfection-Testing-and-Treatment.html ... healthcare-associated infections (HAIs), demand has increased ...
(Date:8/20/2014)... Aug. 20, 2014 Reportlinker.com announces that ... its catalogue: The Impact of Healthcare ... http://www.reportlinker.com/p01618927/The-Impact-of-Healthcare-Reform-PPACA-On-the-US-IVD-Industry.html The ... is complex legislation that affects virtually every aspect ... are beginning to take effect now. IVD manufacturers ...
(Date:8/20/2014)... , Aug. 20, 2014 ... report is available in its catalogue: ... France, Key Trends and Opportunities to 2018 ... Synopsis The report provides in depth ... French personal accident and health insurance segment, ...
Breaking Medicine Technology:The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment) 2The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment) 3The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment) 4The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment) 5The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment) 6The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 2The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 3The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 4The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 5The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 6Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 2Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 3Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 4Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 5Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 6Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 7Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 8Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 9Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 10Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 11Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 12Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 13Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 14Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 15Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 16Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 17Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 18Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 19Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 20Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 21Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 22Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 23
... - Biovest,International, Inc. (OTCBB: BVTI), a majority owned ... 2007 blinded interim data from the start of ... for Non-Hodgkin's,lymphoma (NHL) from September 2000 through June ... data that has been made available,to the Company ...
... at the 11th International Myeloma Workshop -, NORTH ... -- The International Myeloma Foundation (IMF) --,supporting research ... families, researchers and physicians -- today,said that updated ... Greece demonstrate improved survival for a wide,range of ...
Cached Medicine Technology:Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable,Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical,Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkin's Lymphoma 2Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable,Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical,Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkin's Lymphoma 3Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable,Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical,Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkin's Lymphoma 4Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable,Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical,Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkin's Lymphoma 5The International Myeloma Foundation Says Data Reported at a Global,Medical Meeting in Greece Demonstrates Improved Survival for a Wide,Range of Myeloma Patients 2The International Myeloma Foundation Says Data Reported at a Global,Medical Meeting in Greece Demonstrates Improved Survival for a Wide,Range of Myeloma Patients 3The International Myeloma Foundation Says Data Reported at a Global,Medical Meeting in Greece Demonstrates Improved Survival for a Wide,Range of Myeloma Patients 4
(Date:8/20/2014)... 2014 According to a new ... Diagnostics Market (Technologies: Very High, High, Medium, Low ... Diagnosis, Oncology, Autoimmune Diseases, Cardiac, Allergies and Others) ... and Forecast, 2013 - 2019", the global multiplexed ... in 2012 and is expected to grow at ...
(Date:8/20/2014)... New York, NY, August 20, 2014 Transrectal ultrasound ... cancer, but international reports have suggested that the number ... a new nationwide population-based study, Swedish researchers found that ... for a urinary tract infection within 30 days after ... hospital admissions over five years, reports The Journal ...
(Date:8/20/2014)... 2014 Ticket Down is a reliable ... FL at the Sun Life Stadium in early September. , ... when Brazil and Colombia meet at Sun Life Stadium in Miami ... teams in the world and will be a rematch of their ... will kick-off on Sept. 5 and will feature some of the ...
(Date:8/20/2014)... It’s no secret that millions of Americans ... Institute on Drug Abuse, nearly 24 million Americans are ... alarming is the fact that the total number of ... locked in a struggle with substance abuse often feel ... the newly-redesigned AbuseTreatmentCenters.net has released updated lists of ...
(Date:8/20/2014)... 20, 2014 A Missouri federal judge has ... who were treated with GranuFlo and NaturaLyte to the City ... of Baron and Budd. The judge rejected an assertion by ... they were invalid. (McGee, et al. v. Fresenius Medical Care ... Fresenius Medical Care, is the manufacturer of the dialysis products ...
Breaking Medicine News(10 mins):Health News:Multiplexed Diagnostics Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 2Health News:Multiplexed Diagnostics Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 3Health News:Multiplexed Diagnostics Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 4Health News:Severe infections with hospitalization after prostate biopsy rising in Sweden 2Health News:Brazil vs. Colombia Tickets in Miami, FL: Ticket Down Slashes Colombia vs. Brazil Tickets at Sun Life Stadium in Miami for Sept. 5th Match 2Health News:Brazil vs. Colombia Tickets in Miami, FL: Ticket Down Slashes Colombia vs. Brazil Tickets at Sun Life Stadium in Miami for Sept. 5th Match 3Health News:Re-Launched AbuseTreatmentCenters.net Offering New List of Substance Abuse Resources 2Health News:GranuFlo/NaturaLyte Case Remanded to State Court By Missouri Federal Judge, Baron and Budd Reports 2
... WEST PALM BEACH, Fla., Aug. 25 For years, millions ... pantyhose to cover up unsightly varicose and spider veins. Now there,s ... Garden of Life,s ( www.gardeno f life.com ... clinical studies and millions of happy European women. , , ...
... ORLEANS, Aug. 25 Over 102,000 Americans are ... and a Slidell, Louisiana resident is making the most of his ... for the 2010 Transplant Olympics, twittering his progress, and furthering his ... a unique and personal level of hope and understanding by caring ...
... Study Suggests Division, Ambivalence and Hesitancy to Change; Demographics ... Aug. 25 Americans lack confidence that healthcare reform will deliver ... released today by the Thomson Reuters. , , ... a wide range of issues including the cost and quality of ...
... ... the aging eye , ... Francisco, CA (Vocus) August 25, 2009 -- EyeCare America, a national non-profit organization that provides ... a healthy aging eye in honor of September,s Save Your Sight Month., , , , ...
... ... of Honolulu are celebrating the fifth anniversary of their successful partnership by holding an ... ... healthcare education company, and Kapi,olani Community College of Honolulu are celebrating the fifth anniversary ...
... ... honest and forthright look at why Americans are overweight, overwhelmed, and confused, and ... ... (PRWEB) August 25, 2009 -- The question is not whether Americans are getting ...
Cached Medicine News:Health News:Garden of Life Launches Lovely Legs(TM) to Reduce Visible Signs of Varicose and Spider Veins 2Health News:Double Recipient Twitters Transplant Olympic Training and Tackles Nursing School 2Health News:Thomson Reuters Survey: Americans Skeptical that Healthcare Reform Will Improve Quality or Affordability 2Health News:Thomson Reuters Survey: Americans Skeptical that Healthcare Reform Will Improve Quality or Affordability 3Health News:EyeCare America Promotes Healthy Aging Tips During September's Save Your Sight Month 2Health News:EyeCare America Promotes Healthy Aging Tips During September's Save Your Sight Month 3Health News:EyeCare America Promotes Healthy Aging Tips During September's Save Your Sight Month 4Health News:Career Step and Kapi'olani Community College Celebrate Five Year Partnership 2Health News:The Naked Truth: Overweight, Overwhelmed and Confused 2
The Calcitonin ELISA is intended for the quantitative determination of Calcitonin in human serum....
... wavelength (532 nm and 940 nm) laser ... solution. This solid-state laser quickly and effectively ... vulgaris. VariLite offers the clinical versatility to ... deeper, larger vessels in a convenient, affordable ...
... PREMIUM SURGICLIP™ clip applier consists of an applier ... 15 or 20 titanium clips. , ,The ... or other tubular structure. As the handles of ... closed around the vessel or structure. As the ...
The LIGACLIP ERCA Endoscopic Rotating Multiple Clip Applier is intended for use on tubular structures or vessels wherever a metal ligating clip is indicated. The tissue being ligated should be consis...
Medicine Products: